Preclinical study of therapeutic strategy for Lafora disease shows promise

A team of scientists have designed and tested in mice a novel and promising therapeutic strategy for treating Lafora Disease (LD), a fatal form of childhood epilepsy. This new type of drug—called an antibody-enzyme fusion or AEF—is a first-in-class therapy for LD and an example of precision medicine that has potential for treating other types of aggregate-based neurological diseases.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/preclinical-study-of-therapeutic-strategy-for-lafora-disease-shows-promise